Climb Bio, Inc. (CLYM) company profile
Close on Nov 17, 2026Market cap $561.73MP/E –Yield –
About Climb Bio
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biotechnology business that develops therapies for individuals suffering from immune-mediated conditions. Its pipeline centers on two investigational monoclonal antibodies obtained through acquisitions and licensing: budoprutug and CLYM116. Budoprutug targets CD19 to deplete B cells in conditions such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. CLYM116 targets APRIL to suppress antibody production in immunoglobulin A nephropathy and related disorders. The company's end users are patients with serious autoimmune and inflammatory diseases.
The company conducts clinical development programs across several continents. It maintains or prepares trial sites in the United States, Australia, China, Argentina, Brazil, Georgia, Taiwan, Bulgaria, Greece, Serbia, Spain, Romania, and Ukraine. Additionally, it collaborates with a development partner located in China. The provided text does not disclose the location of the company's headquarters or its physical facilities.
Summary of the business section of Climb Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Climb Bio, Inc.
- Headquarters
- Wellesley Hills, MA
- Address
- 20 William Street, Suite G50
- Phone
- 1-866-857-2596
- Website
- climbbio.com
- Employees
- 28, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Seattle, Washington
Stock & identifiers
- Ticker
- CLYM
- Former tickers
- ELYM until Oct 2, 2024
- Exchange
- Nasdaq
- IPO date
- Aug 11, 2021
- Shares outstanding
- 57M, Jul 31, 2026
- Public float
- $44.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1768446
- CUSIP
- 28658R106
- ISIN
- US28658R1068
- FIGI
- BBG00ZNKL0K6
- Share class FIGI
- BBG00ZNKL0L5
- EIN
- 83-2273741
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Aoife Brennan | President and CEO, Director | 87,731 |
| Susan ALTSCHULLER | Chief Financial Officer | – |
| Perrin Megan Wilson | Chief Business Officer | – |
| Cindy Driscoll | Senior Vice President, Finance | – |
| Emily Pimblett | SVP, Finance & CAO | 18,888 |
| Brett Kaplan | Chief Operating Officer | – |
| RA Capital Nexus Fund II, L.P. | Director | 288,461 |
| Capital Healthcare Fund LP RA | Director | 3,403,429 |
| Rajeev M. Shah | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Peter Kolchinsky | Director | 3,396,318 |
| RA Capital Nexus Fund, L.P. | Director | 20,000 |
| Ra Capital Management, L.P. | Director | – |
| Stephen Basil Thomas | Director | 467,969 |
| Breanna Maurine Celebi | Director | – |
| Andrew David Levin | Director | 0 |
| Douglas E. Williams | Director | – |
| Alexander Cumbo | Director | – |
| Kimberlee C. Drapkin | Director | – |
| Judith Dunn | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Aoife Brennan, M.B., Ch B. President and Chief Executive Officer | $669.50K | $1.83M | $405.05K | $14.00K | $2.92M | -51% |
| Susan Altschuller, Ph.D., MBA Chief Financial Officer (6) | $127.50K | $963.06K | $56.56K | $4.25K | $1.15M | – |
| Perrin Wilson, Ph.D. Chief Business Officer (8) | $406.88K | $794.40K | $228.26K | $107.83K | $1.54M | – |
| Brett Kaplan, M.D. Former Chief Operating Officer (11) | $223.61K | $797.25K | – | $140.87K | $1.16M | -61% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 11, 2021
- Offer price
- $12.50
- Securities offered
- 6,400,000
- Gross proceeds
- $80.00M
- Exchange
- Nasdaq
- First trading day
- Aug 10, 2021
- First-day close
- $15.90+27.2%
- Lock-up ends (est.)
- Feb 6, 2022
“The initial public offering price is $12.50 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 28 full-time employees, and one part-time employee, including a total of six employees with M.D., Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 20, 2024 | Name change | Name changed from Eliem Therapeutics, Inc. to Climb Bio, Inc. |
| Jun 27, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 4, 2024 | Merger vote | Definitive merger proxy statement |
| Aug 11, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 3, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?